Biogen Inc. is shedding Chief Executive Michel Vounatsos and effectively abandoning its high-profile Alzheimer’s disease treatment Aduhelm as it attempts to chart a new course after Medicare’s devastating refusal to pay for it.
Biogen said Tuesday that Mr. Vounatsos, 60 years old, would continue to lead the company and remain on its board until a search for a new CEO is completed. It also took steps that will effectively end its marketing of the Alzheimer’s drug.
